Daiichi – Page 2

AstraZeneca and Daiichi Sankyo’s Dato-DXd Fails to Meet Overall Survival Goal in NSCLC Study, FDA Decision Looms

8 months ago talkbio0Tagged AstraZeneca, Clinical Research, Daiichi, Dato-DXd, Datopotamab deruxtecan, Decision, Non-Small Cell Lung Carcinoma, Overall Survival, Sankyo, TROPION-Lung01, United States Food and Drug Administration

AstraZeneca, Daiichi Sankyo, Dato-DXd (datopotamab deruxtecan), Non-small cell lung cancer (NSCLC), Overall survival (OS), FDA decision, TROPION-Lung01 study

WCLC24: Merck & Daiichi Sankyo’s ADC Shows Promising Results in Small Cell Lung Cancer

8 months ago talkbio0Tagged Antibody-Drug Conjugates, Co., Daiichi, Deruxtecan, DXd, ifinatamab, Sankyo, Small cell carcinoma of lung, Technology, therapeutic autologous dendritic cells, WCLC24

WCLC24, Merck & Co., Daiichi Sankyo, ADC (Antibody Drug Conjugate), SCLC (Small Cell Lung Cancer), Ifinatamab Deruxtecan, DXd ADC Technology

Promising Phase 2 Results for Ifinatamab Deruxtecan in Small Cell Lung Cancer

8 months ago talkbio0Tagged Cell Lung Cancer, Daiichi, Deruxtecan, ifinatamab, Phase 2 trial, Sankyo, Small, Technology, therapeutic autologous dendritic cells

Ifinatamab Deruxtecan, Small Cell Lung Cancer, Phase 2 Trial, ADC Technology, Daiichi Sankyo, Merck

Merck & Co., Daiichi Sankyo Strengthen Partnership with New DLL3 Cancer Drug Agreement

9 months ago talkbio0Tagged Antibody-Drug, Daiichi, DLL3, DLL3 gene, Immunostimulating conjugate (antigen), Merck & Co., MK-6070, Neoplasms, Neurosecretory Systems, Oncology Pipeline, Sankyo, Small cell carcinoma of lung, T-Lymphocyte

Merck & Co., Daiichi Sankyo, DLL3, T-cell engager, MK-6070, small cell lung cancer, neuroendocrine tumors, antibody-drug conjugates, oncology pipeline

Merck and Daiichi Sankyo Collaborate to Develop T-Cell Engager MK-6070 from Harpoon Acquisition

9 months ago talkbio0Tagged Antibody-Drug, Daiichi, DLL3 gene, Harpoon, Immunostimulating conjugate (antigen), Merck, MK-6070, Sankyo, Small cell carcinoma of lung, T-Lymphocyte

Merck, Daiichi Sankyo, T-cell engager, MK-6070, Harpoon Therapeutics, small cell lung cancer, DLL3, antibody-drug conjugates

AstraZeneca and Daiichi Sankyo’s Enhertu Denied NICE Recommendation for NHS Use, Prompting Calls for Review Process Reform

9 months ago talkbio0Tagged AstraZeneca, Cost Effectiveness, Daiichi, Enhertu, Malignant neoplasm of breast, Nance-Horan syndrome, Nitroglycerin/Sodium Citrate/Ethanol Solution, Review Process Reform, Sankyo

Enhertu, NICE, AstraZeneca, Daiichi Sankyo, NHS, breast cancer treatment, cost-effectiveness, pricing dispute, review process reform

Merck and Daiichi Sankyo’s ADC Pact Hits Regulatory Setback in FDA Rejection

10 months ago talkbio0Tagged Antibody-Drug Conjugates, Daiichi, Deruxtecan, HER3 protein, Merck, Non-Small Cell Lung Carcinoma, patritumab, Regulatory Setback, Rejection (Psychology), Sankyo, United States Food and Drug Administration

Merck, Daiichi Sankyo, Antibody-Drug Conjugate (ADC), Patritumab Deruxtecan, FDA Rejection, Regulatory Setback, HER3 Protein, Non-Small Cell Lung Cancer (NSCLC)